

**Table 11.6h**  
**Persistency of Discharge Regimen by Follow-up Period, 2003 to 2007**  
**Recipients with Heart Transplants**

	Year of Transplant				
	2003	2004	2005	2006	2007
<b>Discharge Regimen (w/ or w/o Steroid Use)</b>					
<b>CyA+Aza</b>					
At Discharge (N)	94	84	48	43	30
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
1 Year PostTx (%)	45.2%	63.1%	76.7%	74.4%	72.4%
2 Years PostTx (%)	34.6%	41.3%	41.7%	46.9%	-
3 Years PostTx (%)	29.8%	30.0%	32.3%	46.9%	-
<b>CyA+MMF</b>					
At Discharge (N)	828	752	637	612	547
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
1 Year PostTx (%)	67.4%	77.9%	81.9%	81.0%	79.6%
2 Years PostTx (%)	55.1%	61.3%	65.4%	66.1%	61.6%
3 Years PostTx (%)	47.4%	52.3%	56.4%	55.6%	-
<b>CyA+Siro</b>					
At Discharge (N)	39	2	2	2	-
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	-
1 Year PostTx (%)	51.3%	50.0%	100.0%	50.0%	-
2 Years PostTx (%)	38.5%	50.0%	0.0%	50.0%	-
3 Years PostTx (%)	33.0%	50.0%	0.0%	-	-
<b>Siro+MMF</b>					
At Discharge (N)	19	24	17	25	7
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
1 Year PostTx (%)	63.2%	75.0%	64.7%	87.5%	57.1%
2 Years PostTx (%)	52.6%	58.3%	64.7%	76.6%	57.1%
3 Years PostTx (%)	47.4%	54.2%	47.1%	-	-
<b>Tac+Aza</b>					
At Discharge (N)	26	23	20	27	20
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
1 Year PostTx (%)	60.0%	78.3%	60.0%	77.8%	67.9%
2 Years PostTx (%)	38.8%	60.9%	45.0%	54.9%	-
3 Years PostTx (%)	25.8%	47.8%	36.0%	54.9%	-
<b>Tac+MMF</b>					
At Discharge (N)	572	723	941	1,060	1,237
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
1 Year PostTx (%)	77.2%	83.8%	86.1%	87.5%	86.5%
2 Years PostTx (%)	68.9%	73.4%	75.7%	77.1%	73.2%
3 Years PostTx (%)	62.0%	66.5%	70.1%	72.0%	-
<b>Tac+Siro</b>					
At Discharge (N)	36	19	23	26	7
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%

(Continued)

Source: OPTN/SRTR Data as of May 4, 2009.

## Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.

**Table 11.6h (Continued)**  
**Persistency of Discharge Regimen by Follow-up Period, 2003 to 2007**  
**Recipients with Heart Transplants**

	Year of Transplant				
	2003	2004	2005	2006	2007
<b>Discharge Regimen (w/ or w/o Steroid Use)</b>					
Tac+Siro					
1 Year PostTx (%)	66.7%	55.7%	82.6%	69.2%	85.7%
2 Years PostTx (%)	60.6%	44.6%	69.6%	64.9%	-
3 Years PostTx (%)	57.4%	33.4%	58.4%	-	-

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.